Calcitonin News and Research

RSS

Calcitonin is a 32-amino acid linear polypeptide hormone that is produced in humans primarily by the parafollicular cells (also known as C-cells) of the thyroid, and in many other animals in the ultimobranchial body.

Winston submits NDA for CIVANEX to U.S. FDA

Winston Laboratories, Inc., a wholly-owned subsidiary of Winston Pharmaceuticals, Inc., a pharmaceutical company focused on developing and commercializing novel pain management therapies, announced that it has submitted a new drug application (NDA) with the U.S. Food and Drug Administration (FDA) for approval to market its civamide (zucapsaicin) 0.075% cream, CIVANEX®, for the treatment of signs and symptoms of osteoarthritis of the knee.

7 Jul 2010

Vandetanib extends Progression Free Survival in ZETA phase III study for advanced medullary thyroid cancer

Results from ZETA, a phase III study in patients with advanced medullary thyroid cancer (MTC), showed that treatment with the investigational drug vandetanib significantly extended Progression Free Survival (PFS), the primary endpoint of the study, by demonstrating a 54% reduction in the rate of progression compared to placebo.

8 Jun 2010

Novartis cancels Emisphere Technologies' Convertible Promissory Note

Emisphere Technologies, Inc. today announced that it has entered into an expanded relationship with Novartis Pharma AG pursuant to which Novartis has cancelled the Company's Convertible Promissory Note. The Note was originally issued to Novartis on December 1, 2004 in connection with the Research Collaboration and Option License Agreement between the parties of that date and was originally due December 1, 2009. Previously, Novartis had agreed to extend the maturity date to June 4, 2010.

4 Jun 2010

Long-term data demonstrates clinical benefits of Exelixis XL184 for medullary thyroid cancer

Exelixis, Inc. today reported long-term results in a cohort of 37 medullary thyroid cancer (MTC) patients who participated in the phase 1 study of XL184. Dr. Razelle Kurzrock from the MD Anderson Cancer Center in Houston, TX will present the data in a Clinical Science Symposium (Abstract #5502) on Monday, June 7 at 10:15 AM at the 2010 Annual Meeting of the American Society of Clinical Oncology in Chicago.

21 May 2010

Emisphere Technologies first-quarter net loss increases to $18.5 million

Emisphere Technologies, Inc. today announced its financial results for the first quarter 2010.

17 May 2010

Unigene first-quarter revenue decreases to $2.5 million

Unigene Laboratories, Inc. has reported its financial results for the quarter ended March 31, 2010.

11 May 2010

Unigene Laboratories enters into amended and restated financing agreement

Unigene Laboratories, Inc. (http://www.unigene.com) today announced that it has entered into an amended and restated financing agreement for $33 million three-year convertible senior secured term notes.

17 Mar 2010

FDA approves Novo Nordisk's Victoza for type 2 diabetes

Novo Nordisk, a global healthcare company, announced today the U.S. Food and Drug Administration (FDA) approved the new drug application for Victoza® (liraglutide [rDNA origin] injection), the first once-daily human glucagon-like peptide-1 (GLP-1) analog for the treatment of type 2 diabetes. Victoza is indicated as an adjunct to diet and exercise to improve blood sugar control in adults with type 2 diabetes mellitus.

27 Jan 2010

Unigene Laboratories files shelf registration statement with Securities and Exchange Commission

Unigene Laboratories, Inc. (OTCBB: UGNE, http://www.unigene.com) announced that it has filed a shelf registration statement on Form S-3 with the Securities and Exchange Commission (“SEC”).

24 Dec 2009

Emisphere's oral salmon calcitonin product addresses persistent musculoskeletal pain

Emisphere Technologies, Inc. today announced a meta-analysis published in the December 2009 edition of Rheumatology Reports examining independent evidence of the analgesic action of the hormone calcitonin. This publication restates the potential of calcitonin in filling a significant unmet need for alternative treatments for persistent musculoskeletal pain.

22 Dec 2009

Unigene Laboratories selects UGP281 lead peptide from obesity program for development

Unigene Laboratories, Inc. (http://www.unigene.com) announced today that it has selected a lead peptide compound, designated UGP281, from its obesity program for development.

18 Dec 2009

DMC recommends Novartis and Nordic Bioscience to continue oral calcitonin Phase III studies

Unigene Laboratories, Inc. (http://www.unigene.com) announced that an independent Data Monitoring Committee (DMC) has recommended that Novartis and its partner Nordic Bioscience proceed as planned with their ongoing oral calcitonin Phase III studies for osteoporosis and osteoarthritis.

11 Dec 2009

DMC recommends Emisphere Technologies' to proceed with oral calcitonin trial for OP and OA

Emisphere Technologies, Inc. today announced that an independent Data Monitoring Committee (“DMC”) informed Novartis and its partner Nordic Bioscience about their recommendation to proceed with the Osteoporosis (“OP”) Phase 3 Study 2303 and the Osteoarthritis (“OA”) Phase 3 Study 2301 exploring the safety and efficacy of an oral formulation of salmon calcitonin to treat patients with osteoporosis and osteoarthritis of the knee.

10 Dec 2009

Unigene Laboratories announces reduction in workforce and operating expenses

Unigene Laboratories, Inc. has announced a restructuring plan that includes a reduction in workforce to improve operational efficiencies and to better match resources with market demand and the Company’s strategic objectives.

9 Dec 2009

Emisphere Technologies' key product developments and financial results for the third quarter of 2009

Emisphere Technologies, Inc. today announced financial and operational results for the third quarter and nine months ended September 30, 2009.

9 Nov 2009

Tarsa Therapeutics receives license for Phase III oral calcitonin program

Unigene Laboratories, Inc. and Tarsa Therapeutics, Inc. today announced that Unigene has licensed its Phase III oral calcitonin program to Tarsa, a new company formed by a syndicate of three venture capital funds specializing in the life sciences: MVM Life Science Partners, Quaker BioVentures and Novo A/S.

20 Oct 2009

Oral salmon calcitonin using absorption-enhancing Eligen Technology holds promise for osteoarthritis

Emisphere Technologies, Inc. announced study results in which twice-daily oral salmon calcitonin using Emisphere’s proprietary Eligen® Drug Delivery Technology significantly suppressed markers of cartilage and bone degradation versus placebo in men and women with osteoarthritis, the most common form of arthritis.

19 Oct 2009

Merck update on the status of telcagepant clinical development programs

Merck & Co., Inc. today updated the status of the clinical development programs for telcagepant (MK-0974) and MK-3207, the Company's investigational oral calcitonin gene-related peptide (CGRP) receptor antagonists for the intermittent treatment of acute migraine.

11 Sep 2009

Validity of Unigene’s patent on Fortical confirmed by the court

Unigene Laboratories, Inc. has reported that the U.S. District Court, Southern District of New York, has confirmed the validity of Unigene’s patent on Fortical and issued an order permanently enjoining Apotex Inc. and Apotex Corp. from further infringement of the patent.

3 Sep 2009

Unigene Labs reports financial results for three months ended June 30, 2009

Revenue for the three months ended June 30, 2009 was $4,297,000, compared to $4,978,000 for the three months ended June 30, 2008. Revenue for both periods primarily consisted of Fortical sales and royalties, which were $3,807,000 for the three months ended June 30, 2009, and $4,110,000 for the three months ended June 30, 2008.

11 Aug 2009